Table 1.
Patients baseline characteristics
| Characteristics | HC | CKD G3–G4 | HD | KT |
|---|---|---|---|---|
| Patients, n | 10 | 12 | 11 | 15 |
| Age (yr), mean±SD | 12.1±4.2 | 8.3±2.3 | 13.6±3.2 | 9.1±2.9 |
| Female, n (%) | 7 (70) | 5 (42) | 3 (27) | 6 (40) |
| Diagnosis, n (%) | ||||
| CAKUT | N/A | 5 (42) | 5 (45) | 8 (53) |
| Tubulointerstitial | N/A | 2 (17) | 1 (9) | 3 (20) |
| Glomerulopathy | N/A | 4 (33) | 4 (36) | 3 (20) |
| Post-AKI | N/A | 1 (8) | 1 (9) | 1 (7) |
| Healthy | 10 (100) | N/A | N/A | N/A |
| Weight (percentile), mean±SD | 61±23 | 38±21 | 8±7 | 52±28 |
| BMI (percentile), mean±SD | 57±21 | 35±19 | 31±19 | 59±25 |
| eGFR (ml/min per 1.73 m2), mean±SD | 100.2±29.3 | 29.6±14.6 | 6.6±1.1 | 78.6±19.4 |
| Urea (mg/dl), mean±SD | 30±7 | 112±67 | 147±39 | 36±14 |
| Uric acid (mg/dl), mean±SD | 4.8±1.3 | 7.6±2.2 | 6.7±1.2 | 5.4±1.4 |
| Phosphate (mmol/L), mean±SD | 1.3±0.1 | 1.6±0.3 | 2.0±0.5 | 1.5±0.3 |
| Albumin (g/L), mean±SD | 47.7±5.3 | 43.8±13.0 | 38.0±4.8 | 40.0±3.4 |
| CrP (mg/L), mean±SD | 0.4±0.16 | 0.8±1.0 | 1.7±1.6 | 2.1±1.8 |
| PTH (pmol/L), mean±SD | N/A | 13.2±8.5 | 38.5±38.4 | 7.7±3.8 |
| Triglycerides (mg/dl), mean±SD | N/A | 166±75 | 186±54 | 112±57 |
| Proteinuria (mg/g), n (%) | N/A | N/A | ||
| <30 | 7 (58) | 15 (100) | ||
| 30–300 | 4 (33) | |||
| >300 | 1 (8) | |||
| Antihypertensive treatment, n (%) | 0 (0) | 10 (83) | 10 (91) | 8 (53) |
| Antihypertensive drugs, n | 0 | 1.8±1.5 | 2.4±1.9 | 0.8±0.9 |
| Arterial hypertension (BP >95th percentile), n (%) | N/A | 2 (17) | 6 (55) | 5 (33) |
Patients (N=48) were grouped into four categories (patients with CKD, those on HD, patients after KT, and HCs). BMI, body mass index; CAKUT, congenital anomalies of the kidney and urinary tract; CrP, C-reactive protein; N/A = not applicable; post-AKI, patients with CKD after AKI; PTH, parathyroid hormone.